

CUSTOMIZING CANCER INSIGHTS




HLIQ™ ONCOLOGY




HUMAN LONGEVITY, INC. (HLI) Oncology provides oncologists with in-depth analysis to guide decisions about personalized cancer therapy based on comprehensive genomic profiling, and a cutting-edge path to informed personalized cancer therapy.

HLI analyzes data from many external sources for approved cancer treatments and cancer clinical trials, as well as public databases and scientific and medical journal publications. Paired with our sequencing techniques, these data are then integrated in our proprietary HLI database to provide a foundation for the latest understanding of molecular targets of cancer and the available treatment options to aide physicians, patients, and care teams.

WHAT WE ARE TESTING




Normal DNA Vs. Tumor DNA: Compare to determine what is different in the tumor.



Tumor RNA: Understand what proteins are being expressed to target treatment.

THE HLI ADVANTAGE



HLIQ ONCOLOGY

The most precise measurements of solid state cancer tumors enabling individualized therapy selection and cancer management.

HLI Oncology offers three products:

HLIQ CANCER EXOME

This test provides exome sequencing of the patient's germline and tumor DNA plus mutational burden of the tumor to guide treatment options, including if a patient is a candidate for immunotherapy.


HLIQ Cancer Exome can:

- Confirm diagnosis
- Identify if a patient may benefit from immunotherapeutics
- Determine inherited cancer risk
- Identify related mutations that may explain the cancer
- Identify opportunities for off-label use of an approved drug
- Identify opportunities for clinical trial participation if other treatments fail

CLINICAL UTILITY



TARGETED THERAPY



IMMUNO-ONCOLOGY



INHERITED CANCER RISK

HLIQ INHERITED CANCER

For family members who want to understand if they may be predisposed to a higher risk of developing cancer, physicians can order this test which examines genes associated with a spectrum of cancers, including common and rare cancer types.

HLIQ COMPREHENSIVE CANCER

Our Comprehensive Cancer research program combines the power of genomics and computing advances that we use in our Cancer Exome testing but includes more in-depth sequencing coverage and analysis on the full genome of both the patient and the tumor. We do Whole Genome sequencing of the germline DNA, tumor DNA, somatic exome, deep sequencing of cancer genes and RNA sequencing to help guide decisions toward cancer management.

Human Longevity, Inc. is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI's business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit humanlongevity.com or healthnucleus.com.

THE PROCESS



1 Genomic testing is used to determine eligibility for a targeted therapy, the potential benefit of immunotherapy as well as links to inherited cancer risks.



2 Next, HLI works with lab and patient to ensure the appropriate samples are collected, including a blood sample and a sample of the patient's tumor tissue.



3 Coordinate with our internal client services personnel to submit a sample for analysis.



4 Results are returned within three to four weeks of obtaining the necessary samples.

Let HLI Be Your Health Intelligence Partner

4570 EXECUTIVE DRIVE
SAN DIEGO, CA 92121

HUMANLONGEVITY.COM
844.838.3322